Neo Non-Randomized hypertension study
NCT ID NCT01471834
First seen Sep 10, 2026 · Last updated Sep 10, 2026
Summary
To assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834) participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Start date
-
Jun 2011
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Actively participating in the Neo Non-Randomized Hypertension Study. * Have signed a revised approved informed consent form for continued participation in this study. Exclusion Criteria: * Treating physician decision that the subject should not continue with therapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for High blood pressure are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Goettingen-Georg August University
Göttingen, 37075, Germany
-
Klinkum St. George Leipzig
Leipzig, 04129, Germany
-
London-Lawson Health Research Institute
London, Ontario, N6G 2V2, Canada
-
Maastricht University
Maastricht, HX6229, Netherlands
-
Midizinische Hochschule Hannover
Hanover, 30625, Germany
-
University Hospital Cologne
Cologn, 50924, Germany
-
University Hospital Duesseldorf
Düsseldorf, 40225, Germany
-
University of Alberta - Edmonton
Edmonton, Alberta, T2P 1C4, Canada
-
University of Calgary
Calgary, Alberta, T2N 2T9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an 8-Week alcohol break lower blood pressure and protect the heart?
- Can a blood pressure drug reverse heart scarring after aortic repair?
- One pill to shield the heart? a polypill aims to prevent heart failure in diabetes
- Could a triple therapy tackle diabetes, high blood pressure, and arthritis at once?
- Can a prescription for produce beat high blood pressure?
- Could hidden hormone cycles be causing Hard-to-Treat high blood pressure?